scholarly journals Gambaran Kepatuhan Minum Obat Pada Pasien TB Paru : Literature Review

2021 ◽  
Vol 1 ◽  
pp. 1863-1874
Author(s):  
Pinaka Swasti Ratu Suryantari ◽  
I Irnawati

AbstractCompliance in treatment and taking Anti Tuberculosis Drugs (OAT) in pulmonary TB Patients is very necessary for consistency in increasing the success rate of treatment. Pulmonary TB Treatment must be done regularly. Otherwise, resistance to Anti Tuberculosis Drugs (OAT) will occur, the duration of taking the drug will be longer, and there will be an increase in the dose consumed. Especially, it is about an adherence to take OAT in patients with Multy-Drug Resistant (MDR) TB and TB with HIV. To find out the description of medication adherence in pulmonary TB patients and and characteristics in pulmonary TB patients. This study used a literature review design. The pill count compliance measurement method was conducted through a keyword search and used 5 articles from Google Scholar, ProQuest, and PubMed published in 2017 – 2021. From the 5 articles reviewed, the results showed that most of the respondents were male (68% or 314 respondents). The education level of most of the respondents was elementary school education (34% or 105 respondents). Most of the respondents were employed (62% or 164 respondents). Compliance with taking medication in pulmonary TB patients was 322 (70%) compliant, given intervention was 159 (92%) compliant, without intervention was 163 (56%) compliant, MDR TB non-adherent was 105 (95%), and TB with HIV 135 was (86%) complied. Compliance with taking Anti Tuberculosis Drugs (OAT) in pulmonary TB patients must be continuously improved and maintained to achieve the World Health Organization's target of increasing the success of pulmonary TB treatment consistently at results of 90%.Keywords: Compliance, Taking Medicines, TB Drugs, Pill Count, and Pulmonary TB AbstrakKepatuhan dalam pengobatan dan minum Obat Anti Tuberkulosis (OAT) pada pasien TB Paru sangat diperlukan konsistensinya dalam meningkatkan angka keberhasilan pengobatan. Pengobatan TB Paru harus dilakukan secara teratur, jika tidak akan terjadi resistensi pada Obat Anti Tuberkulosis (OAT), semakin lama durasi minum obat dan terjadi peningkatan dosis yang dikonsumsi. Terutama kepatuhan minum OAT pada pasien TB Multy Drug Resistant (MDR) dan TB dengan HIV. Mengetahui gambaran kepatuhan minum obat pada pasien TB Paru dan karakteristik pada pasien TB Paru. Desain Literature Review dengan metode pengukuran kepatuhan pill count melakukan pencarian melalui kata kunci dan menggunakan 5 artikel dari database hasil penulusuran elektronik pada Google Cendekia, ProQuest, Pubmed yang dipublish pada tahun 2017 – 2021. Dari 5 artikel yang di review di dapatkan hasil responden pada artikel sebagian besar berjenis kelamin laki – laki yaitu 314 (68%). Tingkat pendidikan responden sebagian besar berpendidikan SD yaitu 105 (34%), dan sebagian besar responden bekerja yaitu 164 (62%). Kepatuhan minum obat pada pasein TB dengan mengabaikan intervensi yang diberikan yaitu 322 (70%) patuh, diberikan intervensi 159 (92%) patuh, tanpa intervensi yang diberikan 163 (56%) patuh, TB MDR tidak patuh 105 (95%), dan TB dengan HIV 135 (86%) patuh. Kepatuhan minum Obat Anti Tuberkulosis (OAT) pada pasien TB Paru harus terus ditingkatkan dan dipertahankan untuk mencapai target World Heatlh Organisation dalam meningkatkan keberhasilan pengobatan TB Paru secara konsisten pada hasil ≥ 90%.Kata kunci: Kepatuhan; Minum Obat; Obat TB; Pill Count; dan TB Paru

Author(s):  
Ayinalem Alemu ◽  
Zebenay Workneh Bitew ◽  
Getu Diriba ◽  
Balako Gumi

The emergence of drug-resistant tuberculosis (DR-TB) is becoming a challenge to the national TB control programs including Ethiopia. Different risk factors are associated with the emergence of DR-TB. Identifying these risk factors in a local setting is important to strengthen the effort to prevent and control DR-TB. Thus, this study aimed to assess the risk factors associated with drug-resistant TB in Ethiopia. The Preferred Reporting Items for Systematic Reviews and Meta-analysis checklist was followed to conduct this study. We systematically searched the articles from electronic databases and gray literature sources. We used the Joanna Briggs Institute Critical Appraisal tools to assess the quality of studies. Data were analyzed using STATA version 15. We estimated the pooled OR along with 95%CI for each risk factor. The heterogeneity of the studies was assessed using the forest plot and I heterogeneity test. Besides, we explored the presence of publication bias through visual inspection of the funnel plot and Egger’s regression test. After intense searching, we found 2238 articles, and 27 eligible studies were included in the final analysis. Based on the pooled analysis of the odds ratio, unemployment (OR; 2.71, 95% CI; 1.64, 3.78), having a history of the previous TB (OR; 4.83, 95% CI; 3.02, 6.64), having contact with a known TB patient (OR; 1.72, 95% CI; 1.05, 2.40), having contact with a known MDR-TB patient (OR; 2.54, 95% CI; 1.46, 3.63), and having pulmonary TB (OR; 1.80, 95% CI; 1.14, 2.45) were found to be the risk factors of drug-resistant TB. While older age TB patients (OR; 0.77, 95% CI; 0.60, 0.95) including age above 45 years OR; (0.76, 95% CI; 0.55, 0.97), and males (OR; 0.86, 95% CI; 0.76, 0.97) were found to had lower risk of DR-TB compared to their counterparts. A previous history of TB treatment is a major risk factor for acquiring DR-TB in Ethiopia that might be due to poor adherence during the first-line anti TB treatment. Besides, having contact with a known TB patient, having contact with a known MDR-TB patient, having pulmonary TB, and being unemployed were the risk factors of DR-TB in Ethiopia. Thus, active screening of TB contacts for DR-TB might help to detect DR-TB cases as early as possible and could help to mitigate its further transmission across the community.


Author(s):  
Ayu Kurniati ◽  
Enny Fitriahadi

IN 2013, the World Health Organization, released data in the form of Maternal Mortality Rate (MMR) worldwide, and the number reached 289,000 per 100, 000 live births, which 99% of cases occurred in developing countries. Research aims to discover the relationship of antenatal class towards mothers’ knowledge of the dangerous sign during pregnancy. The result showed that there is a relationship of antenatal class towards mothers’ knowledge of dangerous sign during pregnancy, From this result, the researcher concludes that antenatal class could increase mothers’ knowledge of dangerous sign during pregnancy and may decrease the complication risk during the childbirth.


2018 ◽  
Vol 16 (1) ◽  
pp. 95-109 ◽  
Author(s):  
María Alejandra Rodríguez-Echeverría ◽  
Angélica María Páez-Castro

A number of factors and conditions hinder and restrict access to the health care system and its different services; these barriers to access put at risk the health of people by affecting adequate processes. Objective: To carry out a literature review on barriers to access to the health care system and visual health services in Colombia and around the world. Methodology: A literature review was carried out based on a search of the Medline, ScienceDirect, and Pubmed databases, as well as indexed public health journals and the websites of the Local Health Authority, the World Health Organization, the Pan American Health Organization, the UNESCO, and the Brien Holden Vision Institute. Results: The main barriers related to demand, both in general services and in visual health, are the lack of perception on the need for service and lack of economic resources; at the offer level, the existing policies constitute a real obstacle. Conclusions: Awareness-raising in the population, together with the implementation of health policies that grant equal access to health care services, are fundamental to prevent people from being affected, to a large extent, by barriers related to demand or offer, regardless of their location or level of income.


Author(s):  
Srijan Goswami ◽  
Sagarika Mitra ◽  
Piyasee Paul ◽  
Dipjyoti Dey ◽  
Sankalan Das

The biochemic system of medicine, also known as the inorganic cell salt therapy, pioneered by Dr. Wilhelm Heinrich Schuessler, following the footsteps of Dr. Samuel Hahnemann, is the oldest form of nutraceutical therapy approved and recognized by the World Health Organization as one of the complementary therapies. The chapter presents the fundamental ideology and concepts that underlies the promising system of biochemic medicine as concisely, simply, and to-the-point as possible. The chapter begins with a brief introduction to biochemic system, nutrition science, and concepts of nutraceuticals, followed by a brief history and literature review. It covers biochemic system of medicine and its relevant concepts before closing the chapter with a conclusion.


2020 ◽  
Vol 10 (7) ◽  
pp. 2605 ◽  
Author(s):  
Christian Lienhardt ◽  
Mario C. Raviglione

The World Health Organization (WHO) End Tuberculosis (TB) Strategy has set ambitious targets to reduce 2015 TB incidence and deaths by 80% and 90%, respectively, by the year 2030. Given the current rate of TB incidence decline (about 2% per year annually), reaching these targets will require new transformational tools and innovative ways to deliver them. In addition to improved tests for early and rapid detection of TB and universal drug-susceptibility testing, as well as novel vaccines for improved prevention, better, safer, shorter and more efficacious treatments for all forms of TB are needed. Only a handful of new drugs are currently in phase II or III clinical trials, and a few combination regimens are being tested, mainly for drug-resistant TB. In this article, capitalising on an increasingly rich medicine pipeline and taking advantage of new methodological designs with great potential, the main areas where progress is needed for a transformational improvement of treatment of all forms of TB are described.


2017 ◽  
Vol 7 (2) ◽  
pp. 86-89 ◽  
Author(s):  
Nourjahan Laskar ◽  
Md Akram Hossain ◽  
Jannatul Fardows ◽  
Mominur Rahman

Background: The World Health Organization has endorsed the use of molecular methods for the detection of tuberculosis (TB) and drug resistant TB as a rapid method. In Bangladesh, the Xpert MTB/RIF assay has been implemented into reference laboratories for diagnosis of TB and also MDR TB.Objective: Drug resistant tuberculosis has long been a common problem prevailing in our country. The present study focused on the rapid identification of Mycobacterium tuberculosis as well as drug resistance.Materials and Methods: Sputum samples from a total of 107 cases, assumed as multi-drug resistance tuberculosis, were studied through GeneXpert assay.Results: Out of 107 cases, 91 (85.05%) were detected having M. tuberculosis ? 64 (59.81%) were rifampicin sensitive and 27 (25.23%) were rifampicin resistant. The sensitivity and specificity of the GeneXpert are 87.64% and 75% respectively.Conclusion: GeneXpert assay can be considered for the rapid diagnosis of drug resistant tuberculosis.J Enam Med Col 2017; 7(2): 86-89


Author(s):  
Rajendra Prasad ◽  
Harsh Saxena ◽  
Nikhil Gupta ◽  
Mohammad Tanzeem ◽  
Ronal Naorem

AbstractDrug-resistant tuberculosis (DR-TB) has been an area of growing concern and posing threat to human health worldwide. The treatment has been defined for all types of DR-TB with or without newer anti-TB drugs. multi-DR-TB (MDR-TB) patients have now choice of two types of regimen, shorter and longer regimens. Shorter regimen for treatment of subset of MDR-TB patients who have not been previously treated with second line drugs and in whom resistance to fluoroquinolones and second-line injectable agents has been excluded is given for 9 to 11 months. A longer regimen of at least five effective anti-TB drugs (ATDs) during the intensive phase is recommended, including pyrazinamide and four core second-line ATDs. Intensive phase, including injectables, should be given for at least 8 months. The total duration of treatment is at least 20 months, which can be prolonged up to 24 months depending on the response of the patient. World Health Organization (WHO) has recently revised the grouping of ATD for use in DR-TB patients in 2018 into three groups based on individual patient data meta-analysis depending on their individual efficacy, risk of relapse, treatment failure, and death. Recently, an all oral longer regimen comprising bedaquiline, pretomanid, and linezolid (BPal regime) for 6 to 9 months for extensive-DR-TB (XDR-TB) patients and those MDR-TB patients who cannot tolerate or do not respond to conventional MDR-TB regimen. These new developments will be a step forward toward establishing universal regimen to treat all types of DR-TB. This article has summarized the current evidence from literature search to date, including prevalence of DR-TB, types of regimen used and the advancement in the regimens for effective treatment of DR-TB patients.


2019 ◽  
Vol 23 (10) ◽  
pp. 1050-1054
Author(s):  
L. Guglielmetti ◽  
J. Jaffré ◽  
C. Bernard ◽  
F. Brossier ◽  
N. El Helali ◽  
...  

SETTING: The World Health Organization (WHO) recommends that multidrug-resistant tuberculosis (MDR-TB) treatment should be managed in collaboration with multidisciplinary advisory committees (consilia). A formal national Consilium has been established in France since 2005 to provide a centralised advisory service for clinicians managing MDR-TB and extensively drug-resistant (XDR-TB) cases.OBJECTIVE: Review the activity of the French TB Consilium since its establishment.DESIGN: Retrospective description and analysis of the activity of the French TB Consilium.RESULTS: Between 2005 and 2016, 786 TB cases or contacts of TB cases were presented at the French TB Consilium, including respectively 42% and 79% of all the MDR-TB and XDR-TB cases notified in France during this period. Treatment regimens including bedaquiline and/or delamanid were recommended for 42% of the cases presented at the French TB Consilium since 2009. Patients were more likely to be presented at the French TB Consilium if they were born in the WHO Europe Region, had XDR-TB, were diagnosed in the Paris region, or had resistance to additional drugs than those defining XDR-TB.CONCLUSION: The French TB Consilium helped supervise appropriate management of MDR/XDR-TB cases and facilitated implementation of new drugs for MDR/XDR-TB treatment.


2019 ◽  
Vol 95 (1130) ◽  
pp. 686.2-686
Author(s):  
Paul Nunn

In 2018, tuberculosis (TB) was still among the top 10 leading causes of death, and the leading infectious agent, above HIV/AIDS. An estimated 10 million cases occurred in 2018, with 1.2 million deaths in people uninfected with HIV, and another 250,000 cases of HIV-associated TB. Among all TB cases, 8–6% were HIV infected; 57% were men, 32% women and 11% children (<15 years). About 500,000 cases of rifampicin resistant RR-TB also occurred. Between 2000 and 2018 TB incidence fell on average about 1.6% annually, and 2% between 2017 and 2018. The new global control targets will be presented and recent changes to guidelines positioned in this new scenario.Guidelines for TB management from the UK, US and WHO were reviewed for recent changes. NICE’s 2016 guidance not to screen contacts of non-pulmonary TB met with widespread criticism, but has recently been supported by a cost-effectiveness analysis. A 2019 meta-analysis of the seminal 2014 studies, OFLOTUB, ReMOX and RIFAQUIN trials showed that while none of those trials showed non-inferiority of a four month fluoroquinolone-containing regimen in all patients, those with low smear grade or no cavitation may be treated with 4-month rifampicin containing regimens. ATS/CDC/IDSA guidelines reflect this, but had not been accepted in the UK by October 2019. WHO has recently recommended the use of new agents in the treatment of rifampicin and multi-drug resistant TB. The rapidly-evolving picture of treatment recommendations for MDR-TB will be explained.


Sign in / Sign up

Export Citation Format

Share Document